Drug Profile
AFX 9154
Alternative Names: AFX-9154Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Afecta Pharmaceuticals
- Class Proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Leukaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Leukaemia in USA
- 24 Jun 2008 Clinical trials in Leukaemia in USA (unspecified route)